Inhibition by Nicotinamide of an Homologous PCA Reaction and Antigen-Induced Histamine Release from Rat Peritoneal Mast Cells

Wyczółkowska, J; Maśliński, Cz.

doi:10.1159/000231409

Cited by 13 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Niacinamide has been shown to be a potent inhibitor of cAMP phosphodiesterase and to stabilize mast cells and leukocytes, thereby exerting considerable proteaseand histamine-release blocking activity (27,28). As mentioned previously, histamine and proteases are supposed to take part in the pathogenesis of psoriasis.…”

Section: Brief Review Of the Pharmacology Of Nicotinamide And The Hypmentioning

confidence: 93%

Nicotinamide: a potential addition to the anti‐psoriatic weaponry

Namazi

2003

FASEB j.

View full text Add to dashboard Cite

Psoriasis is an inflammatory disorder characterized by a T helper type 1 cell cytokine pattern. Increased expression of adhesion molecules, prominent neutrophil accumulation, and increased production of nitric oxide are characteristics of this disorder. Moreover, histamine and proteases are supposed to participate in the pathogenesis of psoriasis. Nicotinamide is an inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1) that, through enhancement of nuclear kappa B-mediated transcription, plays a pivotal role in the expression of inflammatory cytokines, chemokines, adhesion molecules, and inflammatory mediators. Through interaction with CD38 and inhibition of IL-1, IL-12, and TNF-alpha production, nicotinamide produces a mild TH2 bias. Nicotinamide is a potent phosphodiesterase inhibitor and suppresses neutrophil chemotaxis and mast cell histamine release. It inhibits nitric oxide synthase mRNA induction and suppresses antigen-induced lymphocyte transformation. Nicotinamide increases the biosynthesis of ceramides, which upon degradation produce sphingosine. Sphingosine inhibits protein kinase C (PKC) and decreases basal cell proliferation dependent on PKC. Taken together, it can be reasoned that nicotinamide could be a useful addition to anti-psoriatic armamentarium. The combination of nicotinamide and thalidomide or methotrexate provided a powerful synergistic inhibition of murine collagen-induced arthritis. Nicotinamide decreased the methotrexate-induced hepatotoxicity. The above combinations may prove to have a powerful anti-psoriatic effect as well. As PARP inhibitors could exert anti-retroviral effect, nicotinamide could also be of special value in the treatment of HIV-infected psoriatics.

show abstract

Section: Brief Review Of the Pharmacology Of Nicotinamide And The Hypmentioning

confidence: 93%

Nicotinamide: a potential addition to the anti‐psoriatic weaponry

Namazi

2003

FASEB j.

View full text Add to dashboard Cite

show abstract

“…An ability of nicotinamide to give a dose-response inhibition of an in vitro histamine release from sensitized mouse peritoneal mast cells during the reaction with an antigen ( fig. 1) is comparable with its effect in preventing the in vitro antigen-in duced histamine release from isolated rat peritoneal mast cells [31].…”

Section: Discussionmentioning

confidence: 80%

“…Also, an in vivo protective action of nicotinamide in guinea pig systemic anaphylaxis was observed [2]. Our previous studies have demonstrated an inhibitory activity of nicotinamide on histamine release in IgE-mediated rat anaphy laxis both in vitro (on actively sensitized isolated peritoneal mast cells) and in vivo (on passively sensitized skin) [31]. It has been found that mouse also produces reaginic antibodies [12,16,18,21,23] and recently they have been identified as IgE class of immunoglobulins [17], similar to IgE identified in man [4,5], monkey [7], rabbit [6] and rat [26].…”

Section: Introductionmentioning

confidence: 99%

Inhibition by Nicotinamide of Antigen-Induced Histamine Release from Mouse Peritoneal Mast Cells

Wyczółkowska

Maśliński

1976

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

The in vitro antigen-induced histamine release from mouse peritoneal mast cells actively sensitized with IgE antibodies was inhibited by nicotinamide. The drug was either given in vivo to the sensitized mice (once daily 100 mg/kg) for 7 days before an in vitro experiment or incubated in vitro (in concentrations 1–40 mm) with sensitized mast cells before an antigen challenge. The possible action of nicotinamide on the mechanisms involved in the regulation of antigen-induced histamine release from mast cells is discussed.

show abstract

“…Thus, it is quite possible that both an inhibitory effect of nicotinamide on PDE and on the decrease of oxidative metabolism in mast cells are responsible for its inhibitory effect on antigen-induced histamine and IgE release [25].…”

Section: Pharmacological Characteristics Of Nicotinamide Relating To mentioning

confidence: 99%

Nicotinamide as a potential addition to the anti-atopic dermatitis armamentarium

Namazi¹

2004

International Immunopharmacology

View full text Add to dashboard Cite

Inhibition by Nicotinamide of an Homologous PCA Reaction and Antigen-Induced Histamine Release from Rat Peritoneal Mast Cells

Cited by 13 publications

References 14 publications

Nicotinamide: a potential addition to the anti‐psoriatic weaponry

Nicotinamide: a potential addition to the anti‐psoriatic weaponry

Inhibition by Nicotinamide of Antigen-Induced Histamine Release from Mouse Peritoneal Mast Cells

Nicotinamide as a potential addition to the anti-atopic dermatitis armamentarium

Contact Info

Product

Resources

About